APA (7th ed.) Citation

S, S., PB, K., HM, V., HG, B., K, D., S, P., . . . AC, R. (2026). The SGLT2 inhibitor empagliflozin promotes increased fatty acid oxidation in skeletal muscle cells. Naunyn-Schmiedeberg's archives of pharmacology, 399(3), 3997. https://doi.org/10.1007/s00210-025-04670-2

Chicago Style (17th ed.) Citation

S, Stevanovic, et al. "The SGLT2 Inhibitor Empagliflozin Promotes Increased Fatty Acid Oxidation in Skeletal Muscle Cells." Naunyn-Schmiedeberg's Archives of Pharmacology 399, no. 3 (2026): 3997. https://doi.org/10.1007/s00210-025-04670-2.

MLA (9th ed.) Citation

S, Stevanovic, et al. "The SGLT2 Inhibitor Empagliflozin Promotes Increased Fatty Acid Oxidation in Skeletal Muscle Cells." Naunyn-Schmiedeberg's Archives of Pharmacology, vol. 399, no. 3, 2026, p. 3997, https://doi.org/10.1007/s00210-025-04670-2.